Navigation Links
Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Date:5/10/2013

SAN DIEGO, May 10, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas. The presentation is scheduled for Wednesday, May 15th at 1 p.m. Pacific Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen Therapeutics to Present at Upcoming Conferences
2. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
3. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
8. Fate Therapeutics Strengthens Its iPSC Platform
9. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
10. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
11. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 Hussey Copper , a ... antimicrobial copper announces Pullman Regional Hospital,s conversion of ... antimicrobial solid touch surface, at a nominal cost.  This ... E-coli and other bacteria within 2 hours of exposure 1 ... bacteria and infectious diseases in its facilities. ...
(Date:7/22/2014)... 22, 2014  United Therapeutics Corporation (NASDAQ: ... release its second quarter 2014 financial results before ... United Therapeutics will host a half-hour teleconference ... Eastern Time.  The teleconference is accessible by dialing ... of the teleconference will be available for one ...
(Date:7/22/2014)... 2014 Dr. Williams says, “Bush has ... recognized that the greatest health care system in the ... needlessly deadly while trying to serve the public. Unfortunately, ... to transform an enormous system that none of them ... his continuing series of Open Letters ( http://is.gd/wdU2CM ) ...
(Date:7/21/2014)... yield so far is small, but chemists at the ... substitution process to make a precursor to transparent thin ... energy devices. , A paper describing the approach is ... of the journal Inorganic Chemistry , which draws ... nuclear chemistry fields. The paper was chosen by the ...
Breaking Biology Technology:Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Dr. Ira Williams Asks What’s Wrong With Jonathan Bush’s Book, Where Does It Hurt? 2Oregon chemists eye improved thin films with metal substitution 2
... , ... goBalto.com introduces a new project management tool - "Projects" - to help ... management tools can be awkward and cumbersome. goBalto Projects takes on project management ... time and money. , ...
... , PHOENIX and SAN CARLOS, Calif., Oct. 10 ... data today from its Phase 2 clinical trial of ... (AAPM) 20th Annual Clinical Meeting in Phoenix, Arizona. ... stage investigational product candidate in clinical development for the ...
... of Toronto have developed a new "lab-on-a-chip" technique that analyses ... at risk of breast cancer much more quickly than ever ... metabolites the products of metabolized estrogen in breast ... patients compared to healthy women, and is therefore believed to ...
Cached Biology Technology:goBalto Introduces Web-based Solution to Manage Drug-development Collaborations 2Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix 2Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix 3Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix 4New lab-on-a-chip technique developed at U of T 2
(Date:7/22/2014)... of planthopper known as Conosimus, which now includes six ... the southern part of the Iberian Peninsula in the ... in the open-access Journal of Insect Science ... Conosimus baenai , has been named after Manuel Baena, ... of Iberian Hemiptera. , Conosimus baenai differs ...
(Date:7/21/2014)... a professor of entomology and cooperating faculty ... the University of California, Riverside, has been awarded the ... of Chemical Ecology ( ISCE ). , Awarded first ... the society,s highest honor. It is awarded annually to ... the study of chemicals that mediate interactions between living ...
(Date:7/21/2014)... to monitor seals, every movement, researchers have shown for ... to offshore wind farms and pipelines. Those man-made structures ... according to a study published in the Cell Press ... , "I was shocked when I first saw the ... Shoal," an offshore wind farm in the United Kingdom, ...
Breaking Biology News(10 mins):UC Riverside entomologist receives international honor for chemical ecology contributions 2Seals forage at offshore wind farms 2
... the egg genome? Researchers have answered a similarly vexing ... of long stretches of repeated DNA in the human genome ... published online by Nature Genetics on October 7, ... the human genome that are partly responsible for both disease ...
... CITY, Utah - Mario R. Capecchi, Ph.D., distinguished professor ... Utahs Eccles Institute of Human Genetics and a Howard ... Prize in Physiology or Medicine. The announcement was ... Karolinska Institute, in Stockholm, Sweden. The prize recognizes Capecchis ...
... of Cincinnati (UC) radiologists have developed a new ... eases diagnosis of venous diseases. Multi-detector computed ... three-dimensional images of arteries, the vessels which carry ... blood throughout the body. Veins, smaller vessels that ...
Cached Biology News:Which came first, the chicken genome or the egg genome? 2Which came first, the chicken genome or the egg genome? 3Gene-targeting pioneer Mario Capecchi shares 2007 Nobel Prize in Medicine 2Gene-targeting pioneer Mario Capecchi shares 2007 Nobel Prize in Medicine 3New thoracic imaging approach can pinpoint underlying venous problems 2